CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?
DOI 10.1055/s-0039-1683741
Bibliografische Angaben
Nachweis in CareLit
Autor:innenT Langbein, HR Kulkarni, A Singh, C Lehmann, C Schuchardt, J Zhang, RP Baum
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe02/2019
Jahrgang / SeitenJg. 58
Kernaussage aus der Literatur
Abstract-Vorschau
Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?
Zitieren
Zitierempfehlung
T Langbein, HR Kulkarni, A Singh, C Lehmann, C Schuchardt, J Zhang, RP Baum (2019) Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?. Nuklearmedizin - NuclearMedicine, 58 (02). https://doi.org/10.1055/s-0039-1683741
Mit CareLit weiterarbeiten